Table 2.
Prognostic factors for survival of CRCLM patients after liver metastasectomy as determined by univariate and multivariate analyses
| Relapse-free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | ||||||||
| > 65 vs. ≤ 65 | 0.73 (0.49–1.08) | 0.115 | 0.86 (0.57–1.29) | 0.461 | 1.01 (0.65–1.57) | 0.968 | 1.19 (0.74–1.93) | 0.470 |
| Gender | ||||||||
| Male vs. female | 1.08 (0.80–1.47) | 0.604 | 1.18 (0.86–1.64) | 0.303 | 0.94 (0.65–1.35) | 0.727 | 0.95 (0.65–1.39) | 0.781 |
| Primary tumor | ||||||||
| Rectal vs. colon | 1.01 (0.74–1.36) | 0.974 | 0.82 (0.60–1.13) | 0.232 | 0.90 (0.63–1.29) | 0.564 | 1.03 (0.70–1.53) | 0.866 |
| Tumor grade | ||||||||
| G3 vs. G1–2 | 1.50 (1.06–2.11) | 0.021 | 1.17 (0.80–1.69) | 0.418 | 1.76 (1.19–2.61) | 0.005 | 1.83 (1.18–2.82) | 0.007 |
| T-stage | ||||||||
| T3–4 vs. Tis-2 | 1.15 (0.78–1.71) | 0.476 | 1.46 (0.95–2.26) | 0.085 | 1.12 (0.70–1.77) | 0.645 | 1.40 (0.83–2.36) | 0.211 |
| N-stage | ||||||||
| N1–2 vs. N0 | 1.53 (1.12–2.09) | 0.007 | 1.47 (1.06–2.04) | 0.021 | 1.79 (1.21–2.61) | 0.002 | 1.68 (1.13–2.48) | 0.010 |
| Preoperative CEA | ||||||||
| > 200 vs. ≤ 200 ng/ml | 1.75 (0.97–3.15) | 0.062 | 2.28 (1.22–4.23) | 0.009 | 1.96 (0.99–3.87) | 0.053 | 3.53 (1.67–7.46) | 0.001 |
| Interval from primary tumor resection to liver metastases | ||||||||
| > 12 vs. ≤ 12 months | 0.90 (0.64–1.27) | 0.538 | 0.73 (0.51–1.06) | 0.099 | 1.11 (00.73–1.69) | 0.634 | 1.42 (0.90–2.24) | 0.128 |
| Number of metastases | ||||||||
| > 1 vs. ≤ 1 | 2.28 (1.64–3.16) | < 0.001 | 1.55 (1.06–2.25) | 0.023 | 1.83 (1.23–2.71) | 0.003 | 1.18 (0.74–1.89) | 0.485 |
| Size of the largest metastasis (cm) | ||||||||
| > 5 vs. ≤ 5 | 1.91 (1.36–2.67) | < 0.001 | 1.56 (1.07–2.26) | 0.021 | 2.75 (1.89–4.01) | < 0.001 | 2.14 (1.41–3.24) | < 0.001 |
| Preoperative chemotherapy | ||||||||
| Yes vs. no | 2.22 (1.62–3.04) | < 0.001 | 2.22 (1.55–3.17) | < 0.001 | 1.41 (0.98–2.03) | 0.064 | 1.44 (0.95–2.21) | 0.090 |
| Postoperative chemotherapy | ||||||||
| Yes vs. no | 0.65 (0.48–0.89) | 0.007 | 0.69 (0.50–0.97) | 0.032 | 0.50 (0.35-0.72) | < 0.001 | 0.46 (0.30–0.69) | < 0.001 |
| Immunoscorea | 0.69 (0.61–0.77) | < 0.001 | 0.73 (0.64–0.83) | < 0.001 | 0.65 (0.56–0.75) | < 0.001 | 0.69 (0.59–0.80) | < 0.001 |
Bold value indicates P < 0.05
HR hazard ratio, CI confidence interval, CEA carcinoembryonic antigen
aAnalyzed as a ranked variable